Navigation Links
Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide
Date:11/25/2013

DUBLIN, November 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/q99tkv/ziopharm) has announced the addition of the "Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


The rationale to develop a stable formulation of palifosfamide is strong: it is the active metabolite of ifosfamide, a well-established alkylating chemotherapy agent. Palifosfamide may spare patients from the toxicities of two other inactive ifosfamide metabolites while retaining its anti-tumor activity. A phase III trial of palifosfamide in first line soft tissue sarcoma (PICASSO III) is underway with progression-free survival results expected later this year. In this report, we review the evidence supporting palifosfamide's development, the likelihood of clinical trial success, key regulatory hurdles as well as the commercial opportunity.

Key Topics Covered:

INTRODUCTION

1. Sarcomas
2. Treatment and prognosis of soft tissue sarcoma
3. Treatment of advanced or metastatic soft tissue sarcoma



PALIFOSFAMIDE

1. Palifosfamide as a single-agent
2. Palifosfamide in combination with doxorubicin
3. Phase I
4. Phase II
5. On-going phase III
6. Phase III trial in small cell lung cancer



CLINICAL AND REGULATORY OPINION

1. The rationale supporting the development of palifosfamide
2. Ifosfamide is active in STS: what does this mean for palifosfamide?
3. Phase II trial of palifosfamide suggests antitumor activity

'/>"/>

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
2. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
3. Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
4. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
5. European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
6. Long Term Follow Up Data On WEB Aneurysm Embolization System Demonstrate High Rate Of Stable Occlusion In Difficult To Treat Aneurysms
7. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
10. Maximum-Strength Formulation Offers Highest Concentration and Purity
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 22, 2014  Sprout Pharmaceuticals today announced positive ... that women treated with flibanserin up to 200 mg at ... were presented at the 20 th Annual Fall Scientific ... America in Miami . ... to the Complete Response Letter and the Formal Dispute Resolution ...
(Date:11/22/2014)... , Nov. 21, 2014 Statistics released from ... drunk driving increase astronomically during the holidays, beginning with ... many cities. The data, highlighted ... Systems as part of their annual Sober ... a picture of high-risk drinking and increased rates of ...
(Date:11/21/2014)... -- Alere Inc. (NYSE: ALR ), a global ... Cunningham as Vice President, Investor Relations. In this ... communications with the investment community. "As we ... increase shareholder value, it is critical that we effectively ... Executive Officer. "We are delighted that Juliet Cunningham ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Alarming Stats Show Holiday Drinking an Issue for Many 2Alere Appoints Juliet Cunningham to Lead Investor Relations 2
... in Neurogastroenterology and Motility- MONTVALE, N.J., Oct. ... announced today the publication of,preclinical data demonstrating the ... of advanced glycated end-products (AGEs) and restore,neuronal nitric ... Loss,of gastrointestinal nNOS activity is one of the ...
... nearly 80% of patients, SAN FRANCISCO, Oct. 24 ... data from an ongoing phase 2,trial of XL880, an ... renal cell carcinoma (PRC). Of 19 patients with measurable,disease ... decrease in,tumor size (4-33%), including one patient with a ...
Cached Medicine Technology:Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications 2Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications 3Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications 4Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer 2Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer 3Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer 4Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer 5
(Date:11/24/2014)... November 24, 2014 "My friend was ... trying to cross the street in his motorized wheelchair," ... saw him. I came up with this idea so ... night." , He developed the Safety Lites to make ... low-lighting conditions. The device ensures that motorists can see ...
(Date:11/23/2014)... 2014 The report, “Market Snapshot: ... 2020 - Asia-Pacific” provides quantitative analysis of the ... minimally invasive body contouring devices, non-invasive body contouring ... market size data by revenue and volume over ... China, Japan, South Korea, Australia and India. It ...
(Date:11/23/2014)... 21, 2014 (HealthDay News) -- Close friends have more ... group does, a new study says. "We,ve ... have an influence on individual alcohol use, but there ... peer group and the friend group,s influence on those ... School of Public Health, said in a university news ...
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity ... was recently featured on International Business Times. ... CEO of American Medical Aesthetics & Wellness, also known ... full scholarship to attend an M.D./Ph.D program at University ... University of Chicago, where his field of study was ...
Breaking Medicine News(10 mins):Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Close Friends May Be Key to Teens' Drinking 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... a large-scale clinical trial presented today at the annual ... provide the first strong evidence of the benefit of ... are at elevated risk for breast cancer. In addition, ... depicting early breast cancer. "We found that annual ...
... , ... new market research report is available in its catalogue: ... Forecasts to 2015 , http://www.reportlinker.com/p0166596/Global-In-Vitro-Diagnostics-Market-Analysis-and-Forecasts-to-2015.html , ... 2015 , Summary , GlobalData,s "Global In ...
... , ... Reportlinker.com announces that a new market research ... The Future of Monoclonal Antibodies - Market Forecasts ... Analysis , http://www.reportlinker.com/p0166816/The-Future-of-Monoclonal-Antibodies---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , ...
... , SACRAMENTO, Calif., Dec. 1 As health care reform ... as a care delivery model, renowned entrepreneur Henry J. Kaiser ... Kaiser,s eldest granddaughter, Carlyn Kaiser Stark, will accept the Spirit ... state ceremony in Sacramento this evening. , Kaiser,s greatest ...
... equal care, very preterm births more likely, British study finds ... are poor are more likely to deliver a very preterm ... receive equal care, a new British study shows. , The ... need to learn more about the association between economic status ...
... to analyze form and structural changes to colorectal liver ... according to research from The University of Texas M. ... in the Dec. 2 issue of JAMA . ... also known as Avastin, is associated with both improved ...
Cached Medicine News:Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 2Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 3Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 4Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 5Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 6Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 7Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 8Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 9Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 10Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 11Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 12Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 13Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 14Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 15Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 16Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 17Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 18Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 19Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 20Health News:Reportlinker Adds Global In Vitro Diagnostics Market Analysis and Forecasts to 2015 21Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Health Care Pioneer Henry J. Kaiser Inducted Into The California Hall of Fame 2Health News:Health Care Pioneer Henry J. Kaiser Inducted Into The California Hall of Fame 3
... as both regular and filter tips. Sterilized ... more efficient sterilization and are delivered with ... of irradiation. Sterilized Diamond Tips are ready ... Diamond Tips are wrapped in medical device ...
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
... to order tips. Each box contains 1000 tips ... contains 200 tips (4 bags of 50 tips). ... 200 tips per pack. Bulk Packs are sealed ... opened for quick access to Gilsons Diamond Tips. ...
Medicine Products: